Education
About Us
Working with TipRanks
Follow Us
Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
GALT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.73 - $3.78
Previous CloseN/A
Volume135.57K
Average Volume (3M)268.65K
Market Cap
$84.03M
Enterprise Value$174.28M
Total Cash (Recent Filing)$120.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.15
Next Earnings
May 19, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding63,180,492
10 Day Avg. Volume230,114
30 Day Avg. Volume268,649
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap2.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.28K
Enterprise Value/Ebitda-4.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
---
Galectin Therapeutics News
PremiumCompany Announcements
Galectin Therapeutics Reports Promising 2024 Results
PremiumCompany Announcements
Galectin Therapeutics Updates Investors on Clinical Trials
PremiumCompany Announcements
Galectin Therapeutics Unveils Promising NAVIGATE Trial Results
PremiumCompany Announcements
Galectin Therapeutics Highlights Promising NAVIGATE Trial Results
---
Bulls Say, Bears Say
Bulls Say
Efficacy DataData in U.S. NAVIGATE per-protocol patients were compelling.
Partnerships And StrategyManagement is working with potential partners and industry experts to determine belapectin’s clinical pathway.
Bears Say
Investor SentimentInvestor sentiment on GALT is now rather poor, given this is the second Phase 2b trial to miss its primary endpoint.
Trial OutcomesThe second Phase 2b study of belapectin failed to reach statistical significance on the primary endpoint.
---
Ownership Overview
27.63% Insiders
4.63% Mutual Funds
0.02% Other Institutional Investors
63.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GALT FAQ
What was Galectin Therapeutics Inc’s price range in the past 12 months?
Galectin Therapeutics Inc lowest stock price was $0.73 and its highest was $3.78 in the past 12 months.
What is Galectin Therapeutics Inc’s market cap?
Galectin Therapeutics Inc’s market cap is $84.03M.
When is Galectin Therapeutics Inc’s upcoming earnings report date?
Galectin Therapeutics Inc’s upcoming earnings report date is May 19, 2025 which is in 25 days.
How were Galectin Therapeutics Inc’s earnings last quarter?
Galectin Therapeutics Inc released its earnings results on Mar 31, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.01.
Is Galectin Therapeutics Inc overvalued?
According to Wall Street analysts Galectin Therapeutics Inc’s price is currently Overvalued.
Does Galectin Therapeutics Inc pay dividends?
Galectin Therapeutics Inc does not currently pay dividends.
What is Galectin Therapeutics Inc’s EPS estimate?
Galectin Therapeutics Inc’s EPS estimate is -0.16.
How many shares outstanding does Galectin Therapeutics Inc have?
Galectin Therapeutics Inc has 63,180,492 shares outstanding.
What happened to Galectin Therapeutics Inc’s price movement after its last earnings report?
Galectin Therapeutics Inc reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -19.737%.
Which hedge fund is a major shareholder of Galectin Therapeutics Inc?
Currently, no hedge funds are holding shares in GALT
---
Galectin Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Insider Transactions
Bought Shares
Worth $7.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.53%
12-Months-Change
Fundamentals
Return on Equity
48.74%
Trailing 12-Months
Asset Growth
-37.96%
Trailing 12-Months
Company Description
Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
---
GALT Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---